| Today’s Big NewsAug 15, 2023 |
| By James Waldron Gilead Sciences' $225 million bet on Arcellx’s CAR-T cell therapy is back in play after the FDA lifted a clinical hold instigated in the wake of a patient death. |
|
|
|
| Philadelphia, PA |  |
|
|
By Max Bayer Galecto's idiopathic pulmonary fibrosis therapy was ineffective in a phase 2 study compared to placebo and recorded a higher rate of serious side effects. The company has discontinued further development, electing to prioritize a clinical-stage treatment for severe liver disease. |
By James Waldron As part of its efforts to develop self-amplifying RNA-based vaccines against a range of infectious diseases, Gritstone bio has tapped regular collaborator Genevant Sciences to again use its lipid nanoparticle tech. |
By Annalee Armstrong Tentarix Biotherapeutics is emerging from its den to ink a multi-pronged deal with Gilead Sciences to work on therapies for oncology and inflammatory diseases worth $66 million upfront, including an equity payment. |
By Max Bayer Alaunos Therapeutics is cutting loose its sole clinical-stage asset and letting 60% of staff go less than two years after rebranding and refocusing on TCR-T cell therapies. |
By Nick Paul Taylor If Juvenescence is as adept at extending the life spans of humans as biotechs, we might all live forever. AgeX Therapeutics, a biotech backed by the longevity specialist, continues to defy Father Time, ending yet another quarter with less than $1 million in the bank and repeating its well-worn going concern warning. |
By Nick Paul Taylor Design Therapeutics is living up to its name. After seeing adverse events in its phase 1 rare disease trial, the biotech has redesigned the formulation to counter the problem—but the developments have set the program back years and triggered a 48% stock drop. |
By Helen Floersh It’s one of life’s hard truths: Once tooth enamel is gone, you can’t get it back. And while tooth tech has come a long way since the days of wooden dentures, there’s no regrowing lost teeth. But with the help of enamel-producing organoids, that may not be the case forever. |
By Fraiser Kansteiner Biogen’s $7.3 billion buyout of Skyclarys-maker Reata Pharmaceuticals surprised some industry watchers last month. But it turns out Biogen wasn’t the only drugmaker jockeying for the Texas-based rare disease outfit, a new securities filing shows. |
By Andrea Park Just as remediation efforts in Philips' massive 2021 respiratory device recall wind down, the company is now facing yet another Class I recall of some of its ventilators. |
By Ben Adams For those of us old enough to remember Vivek Ramaswamy as the founder of Roivant and its continuously expanding group of biotech subsidiaries, his presidential campaign at the age of 38 came as a significant shift in his career trajectory. |
By Heather Landi Amazon Pharmacy will automatically apply drug manufacturer-sponsored coupons on more than 15 insulin and diabetes care brands during online check-out. With the coupons, many insulin brands are available to eligible customers starting at $35 a month with free delivery. |
By Kevin Dunleavy Thanks to sales of their metabolism drugs, Novo Nordisk and Eli Lilly posted the biopharma industry’s largest revenue gains in the second quarter—by far. Meanwhile, only six of the industry’s top 20 firms experienced revenue decreases, with Pfizer's sales dropping a whopping 54%. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss left-handedness and its significance in neurodevelopmental and psychiatric disorder research. |
|
|---|
|
|
|
October 16-17 | Boston, MA Examine the ways the IRA has impacted the drug pricing and access landscape and review business implications for affordability and evaluate strategies for engaging with stakeholders. Secure your spot today and save $400 on registration. Savings end August 21st! 
|
|
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
